PubMed
Randomized controlled trial of oral glutathione supplementation on body stores of glutathione
Richie JP Jr, Nichenametla S, Neidig W, et al. Eur J Nutr. 2015
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 59% · Mixed 23% · Unfavorable overall 18%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.05–3 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 53% said they felt similar to their last entry, 32% more positive, and 18% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 27 days · Based on 21 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 58% · Mixed 30% · Unfavorable overall 12%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 25–600 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 53% said they felt similar to their last entry, 44% more positive, and 18% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 27 days · Based on 67 repeat reporters
Published sources linked on the Glutathione and Semaglutide wiki pages.
PubMed
Richie JP Jr, Nichenametla S, Neidig W, et al. Eur J Nutr. 2015
PubMed
Davids LM, van Wyk JC, Khumalo NP. S Afr Med J. 2016
PubMed
Liu JD, Liu WB, Zhang CY, et al. Fish & shellfish immunology. 2020
PubMed
Hsiao YF, Huang SC, Cheng SB, et al. International journal of molecular sciences. 2024
FDA Drug Label
Novo Nordisk. FDA Drug Label. 2021
FDA Drug Label
Novo Nordisk. FDA Drug Label. 2017
PubMed
Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Weghuber D, Barrett T, Barrientos-Pérez M, et al. N Engl J Med. 2022
PubMed
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. N Engl J Med. 2023
PubMed
Wharton S, Calanna S, Davies M, et al. Diabetes Obes Metab. 2022
PubMed
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. The New England journal of medicine. 2023
PubMed
Ceriello A, Prattichizzo F, Lucisano G, et al. Lancet Reg Health Eur. 2026
PubMed
Wadden TA, Bailey TS, Billings LK, et al. JAMA. 2021
PubMed
Wilding JPH, Batterham RL, Calanna S, et al. Diabetes Obes Metab. 2022
PubMed
Marso SP, Bain SC, Consoli A, et al. N Engl J Med. 2016